Replies to post #333850 on Amarin Corp Plc (AMRN)

[Biobillionair]

@RunningQuarters You are in fact reading it wrong. What will happen May 1 is Vascepa and all related generics will be denied coverage for very high trygs. Generics cannot play in CV so they were relying on off-label/back door. That door is now closed with UHC. My view, worth $5-7 on that determination alone.

When all is said and done cardiovascular indication will be the ONLY reimbursed indication....makes Hikma’s “win” in Nevada hollow but none-the-less damaging to Amarin and shareholders.

Hikma is now whining to Solicitors Generals Office regarding Amarin not requesting an injunction....I find that laughable considering treble damages and potentially add to that punitive damages if Nevada justice is done.

BB